SCHEMBL16908

SCHEMBL16908

CCOC(=O)C(Cc1cccc(OC)n1)NC(=O)CN

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.41
KLKB1 P03952 1/20 0.39
PSMB5 P28074 1/20 0.39
HDAC6 Q9UBN7 4/20 0.39
HDAC1 Q13547 2/20 0.39
ALDH1A1 P00352 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ADORA2A P29274 1/20 0.36
LPAR3 Q9UBY5 2/20 0.36
LPAR1 Q92633 1/20 0.36
TRPM5 Q9NZQ8 1/20 0.36
POLB P06746 1/20 0.36
CTSA P10619 1/20 0.36
MAPT P10636 2/20 0.36
NLRP3 Q96P20 1/20 0.36
LMNA P02545 1/20 0.36
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16909 1.00 TP53 (0.41) TP53KLKB1PSMB5HDAC6HDAC1
SCHEMBL17294 0.81 PTPRB (0.39) TP53PSMB5ALDH1A1MAPT
SCHEMBL17295 0.81 PTPRB (0.39) TP53PSMB5ALDH1A1MAPT
SCHEMBL16971 0.80 NNMT (0.41) PSMB5ALDH1A1ADORA2ACTSA
SCHEMBL16970 0.80 NNMT (0.41) PSMB5ALDH1A1ADORA2ACTSA
SCHEMBL17681 0.77 LOX (0.48) TP53KLKB1ALDH1A1POLBMAPT
SCHEMBL17682 0.77 LOX (0.48) TP53KLKB1ALDH1A1POLBMAPT
SCHEMBL18992 0.76 POLB (0.53) TP53ALDH1A1POLB
SCHEMBL11022951 0.75 TP53 (0.59) TP53ALDH1A1MEN1KMT2APOLB
SCHEMBL11155440 0.75 TP53 (0.59) TP53ALDH1A1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609081-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES Amgen Inc. (US) 2013-07-03 EP disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 TP53 3216/4885KLKB1 1218/4885PSMB5 1949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.